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Summary
Invasive breast cancer is a heterogeneous disease which occurs with diff erent clinical presentations, pathohistological 
characteristics and clinical course. Most common types are invasive ductal carcinoma not otherwise specifi ed (IDC-NOS, 
70-80%) and invasive lobular carcinoma (5 – 15%). Systemic therapy of breast carcinomas is mostly determined by their 
molecular classifi cation, which is based on genetic research of NOS ductal breast cancer, without the inclusion of rare histo-
logical types. Since some rare breast tumors have excellent prognosis despite unfavorable molecular characteristics, when 
deciding on the optimal treatment, both molecular and prognostic characteristics should be considered. Tumors of non-ep-
ithelial origin, such as sarcomas, lymphomas and phyllodes tumors also appear in breasts.
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RIJETKI TUMORI DOJKE
Sažetak
Karcinom dojke je heterogena bolest s raznolikom kliničkom slikom, patohistološkim karakteristikama i kliničkim 
tijekom. Najčešći tipovi karcinoma dojke su invazivni duktalni karcinom (IDC-NOS, 70-80 %) i invazivni lobularni karcinom 
(5-15%). Sustavno liječenje karcinoma dojke temelji se na molekularnoj klasifi kaciji, koja je osnovana na genetskim 
istraživanjima NOS karcinoma, bez uključivanja rijetkih karcinoma dojke. Kako su neki rijetki tumori unatoč nepovoljnim 
molekularnim karakteristikama vrlo dobre prognoze, pri odlučivanju o načinu liječenja rijetkih tumora dojki, osim moleku-
larnih, potrebno je uzeti u obzir i prognostičke karakteristike tih tumora. U dojkama se pojavljuju i tumori neepitelnog po-
rijekla, poput sarkoma, limfoma i phyllodes tumora.
KLJUČNE RIJEČI: rijetki tumori dojki, molekularna klasifi kacija, prognoza, neepitelni tumori
1. INTRODUCTION
Apart from malignant tumors of the skin, 
breast cancer is the most common malignant tu-
mor in women. Invasive breast cancer is a hete-
rogeneous disease which occurs with diff erent 
clinical presentations, pathohistological character-
istics and clinical course. Most cancers originate 
from the epithelium of the terminal ductal lobular 
unit. Predominant histological type is defi ned as 
an invasive ductal carcinoma not otherwise speci-
fi ed, IDC-NOS, which accounts for 70-80 % of all 
breast cancers. The second most common type of 
epithelial cancer is invasive lobular carcinoma, 
which makes 5 – 15 % of all breast cancers (1)
However, there is still a signifi cant number of 
breast cancer types which are less common but are 
clearly defi ned in the World Health Organization 
classifi cation.
Intrisnic classifi cation of breast cancer into 
fi ve subtypes, which determines the choice of ad-
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juvant treatment (2), is defi ned based on genetic 
research of NOS ductal breast cancer, without the 
inclusion of rare histological types. However, 
without knowledge of rare histological types, 
some prognostically favorable rare breast cancers 
may be erroneously classifi ed among the group of 
prognostically unfavorable tumors due to their 
immunohistochemical characteristics, which may 
result in unnecessary aggressive adjuvant treat-
ment. Therefore, when deciding on the optimal 
treatment of rare breast cancer, both molecular 
and prognostic characteristics of rare breast can-
cers should be considered. However, due to a very 
low incidence, there are still no specifi c treatment 
recommendations for some breast tumors. It is 
also extremely important to stress known diff er-
ences in the clinical course of rare tumors and con-
nect all published data on rare tumors with the 
present molecular classifi cation of breast cancers.
Apart from carcinomas, tumors of non-epi-
thelial origin, which will be described later in this 
article, also appear in breasts.
2.  RARE EPITHELIAL MALIGNANT 
BREAST TUMORS
2.1. Pure tubular carcinoma
Pure tubular carcinoma is very rare (less than 
2% of invasive breast carcinoma) and appears 
more often in elderly patients. They are most com-
monly small and regional lymph nodes are rarely 
aff ected (3).These tumors are almost always ER 
and PR positive, well diff erentiated and HER-2 
negative. The prognosis for pure tubular carcino-
ma is excellent, and local recurrence is rare. They 
are most commonly treated with breast-conserv-
ing surgery followed by irradiaton (4). Due to the 
excellent prognosis, the need for determining the 
axillary stage of the disease is questionable (3). 
However, the incidence of axillary metastases can 
be found on 4 – 17 % of cases (,6). SLNB can be 
considered in patients where positive test results 
of lymph nodes could infl uence the choice of adju-
vant treatment. Finally, survival of patients with 
tubular carcinoma is similar to the survival of the 
general population and there is no evidence that 
the addition of adjuvant treatment for positive 
SLN aff ects survival.3
2.2. Invasive cribiform carcinoma
Invasive cribiform carcinoma (ICC) is rare 
(up to 3.5% of all breast cancers). The tumor is of-
ten low graded and slowly growing. It is often dif-
fi cult to diagnose it radiologically so it is frequent-
ly discovered as a palpable mass. It is most often 
ER and PR positive and HER-2 negative. The 
prognosis is excellent, similar to life expectancy 
of general population (7). Distant metastases are 
rarely found. There is no clear specifi c treatment 
for this cancer type.
2.3. Mucinous carcinoma
Mucinous carcinoma has low frequency (1-
4% of all breast cancers), with a bett er prognosis 
than invasive ductal carcinoma (8). It is character-
ized by abundant production of intra- and extra-
cellular mucin. Mucinous carcinoma is divided 
into pure and mixed type. The pure type contains 
above 90% mucin-producing cells, while the 
mixed type (50% - 90% purity) also contains inva-
sive ductal carcinoma cells which do not produce 
mucin (9). The pure type is more often well dif-
ferentiated and has a higher incidence of positive 
ER and PR. Mucinous carcinoma shows a lower 
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incidence of lymphadenopathy in relation to inva-
sive ductal carcinoma (10). It is usually diagnosed 
in older age group (median 71 years) (10). Muci-
nous carcinoma clinically manifests as a palpable 
mass with the lobular lesion clearly visible on the 
mammogramy. Isoechogenicity on ultrasound 
also makes it diffi  cult to detect the tumor (11). 
MRI may be decisive in diagnostics as it shows 
some typical characteristics of this cancer type 
(12,13). Due to its benign appearance, mucinous 
carcinoma is often diagnosed late, but late diagno-
sis does not worsen the clinical outcome (14). Five, 
ten,fi fteen and twenty-year survival is respective-
ly 94 %, 89 %, 85%, and 81 % (15). Axillary meta-
static lesions are a negative prognostic factor and 
appear more commonly in the mixed type. In tu-
mors smaller than 1 cm axillary lymph nodes are 
aff ected in less than 5% of cases (6). However, in 
those cases a SLNB is recommended,since aff ec-
tion of lymph nodes is the most important risk fac-
tor of poor prognosis. Patients with pure muci-
nous carcinoma without invasion of the skin are 
candidates for breast conserving surgery. Adju-
vant systemic therapy is based on treatment rec-
ommendations for common breast cancers (10).
2.4. Solid papillary carcinoma
Solid papillary carcinoma makes up 1.7% of 
all breast cancers. It is characterized by a round 
node with clear margines and low grade ductal 
cells divided by fi brovascular septums. Solid pap-
illary carcinomas often exhibit neuroendocrine 
and mucinous diff erentiation (16). The tumors are 
mostly ER and PR positive and HER2 negative. A 
clinical examination reveals a centrally located 
mass or a bloody discharge from the nipple in el-
derly women. On mammography, the tumor most 
commonly appears as a soft tissue mass with cal-
cifi cations present in less than 50 % of the cases 
(17). In tumors without invasive components the 
prognosis is excellent (16). There are still no spe-
cifi c treatment guidelines for solid papillary carci-
noma.
2.5. Neuroendocrine carcinoma
Neuroendocrine carcinoma of the breast is 
very rare (less than 0.1% of all breast cancers, less 
than 1% of all neuroendocrine tumors) (18). It is 
characterized by neuroendocrine markers (mainly 
chromogranin or synaptophysin) in more than 
50% of cells (19, 20). Histologically, neuroendo-
crinecarcinomas are divided into four subtypes: 
small cell carcinoma (SCC), large cell carcinoma, 
solid neuroendocrine carcinoma and atypical car-
cinoid tumors. Neuroendocrine carcinoma is clini-
cally diagnosed as a palpable mass with clear 
margins on images (21). The tumors are most 
commonly hormone dependent and HER-2 nega-
tive. Immunoprofi le of solid neourendocrine car-
cinoma usually corresponds to luminal A subtype, 
which is why it is assumed this tumor has good 
prognosis, which cannot be said with certainty 
due to very small number of cases. On the other 
hand, SCC is an ER positive tumor with worse 
prognosis. There are still no specifi c treatment 
strategies for the treatment of neuroendocrine tu-
mors of the breast.
2.6. Medullary carcinoma
Medullary carcinoma accounts for 5% of all 
breast cancers (3). It can be divided into classical 
(lymphocytic infi ltrate involves the entire lesion) 
(22), and atypical (proportion of lymphocytic infi l-
trate is reduced) (23,24). Medullary carcinoma is 
mostly diagnosed at a younger age compared to 
ductal invasive carcinoma. The average age of de-
tection is between 45 and 52 years (10). Clinical 
examination reveals a soft consistency tumor with 
sharp edges. ER and HER2 are mostly negative 
and p53 mutation is positive(10). Although it is 
highly proliferative, the prognosis for medullary 
carcinoma is more favorable compared to invasive 
ductal carcinoma (25). Regional lymph node in-
volvement is low (from 16% to 21%) in relation to 
other types of breast cancer (10). BRCA1 positive 
tumors with high grade, negative hormone recep-
tors and p53 somatic mutation have a poor prog-
nosis (24). Such patients usually have pathological 
N stage. Recommended treatment includes breast 
conserving surgery, axillary staging and adjuvant 
treatment. 
2.7. Secretory breast carcinoma
Secretory breast carcinoma accounts for less 
than 0.15% of all types of breast cancer. It is char-
acterized by younger age of onset and indolent 
course. Histological secretory breast cancer per-
tains to the phenotypic spectrum of basal-like 
breast carcinoma, which are characterized by 
presence of intracellular and extracellular secre-
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tory material. It is most commonly detected as a 
painless and hard mass. The carcinoma is mostly 
ER, PR and HER2 negative. Basal-like breast can-
cer marker (epidermal growth factor receptor) is 
present in 90% of the cases. Reported frequency of 
axillary metastases is 20-30%. Nodal involvement 
is rare in children and adolescents. Treatment is 
primarily surgical, including SLNB. The effi  ciency 
of adjuvant chemotherapy and radiation is not 
clear yet. This tumor is associated with high rate 
of long-term survival (26). 
2.8. Adenoid cystic carcinoma
Adenoid cystic carcinoma (ACC) of the breast 
is a very rare tumor responsible for less than 0.1% 
of all breast cancers (27). ACC of the breast can be 
classifi ed as cribriform, tubular and solid. The 
cribriform type is most common. The mean age of 
patients is 50-65 years (28). This tumor presents as 
a 2-3 cm sized nodule. ER, PR and HER 2 are 
mostly negative (27). The prognosis is good. Lym-
phadenopathy and distant dissemination are rare 
( 27,29,30). Patients with negative hormone recep-
tors have a bett er prognosis. ACC is best treated 
with surgery and adjuvant irradiation. Systemic 
therapy is not recommended (27,28).
2.9 Acinic cell carcinoma
Acinic cell carcinoma was described in 1996 
as the equivalent of an identical parotid gland tu-
mor (31). It is very rare, as only 19 cases have been 
documented so far. (32,33). The average age of pa-
tients is 56 years (34,35). Histologically, it is char-
acterized by infi ltrative growth of small glandular 
structures made of cells similar to acinic cells of 
salivary glands. ER, PR and HER2 are negative. 
The prognosis is usually good. Due to the low in-
cidence, there is no consensus on the optimal 
treatment choices.
2.10. Apocrine carcinoma
Apocrine breast carcinoma is microscopically 
defi ned as a type of invasive ductal breast carci-
noma accounting for 0.3-4% of all breast cancers 
(36,37). Apocrine breast carcinoma is clinically 
manifested as a palpable, often multifocal/multi-
centric mass. The tumor usually expresses the an-
drogen receptor (AR), and is ER and PR negative 
(37). On the other hand, HER2 is often overex-
pressed (36). This tumor has a good prognosis 
(38). Apocrine HER2 negative carcinoma has a 
bett er prognosis than non-apocrine triple negative 
carcinoma of the breast due to lower proliferation 
rate. There are no specifi c treatment recommenda-
tions for apocrine breast cancer. Hormonal thera-
py targeted against AR may be applied. Adjuvant 
chemotherapy is recommended for triple negative 
apocrine carcinoma (36).
2.11 Metaplastic carcinoma
Metaplastic carcinoma accounts for 1% of all 
breast cancers and is characterized by presence of 
two cell lines, most commonly malignant epithe-
lial and mesenchymalcomponents (39,40). Aver-
age size at the time of diagnosis is 3.5- 5 cm (41-
44); it rarely aff ects axillary lymph nodes (42,45). 
The mean age of detection is over 50 years of 
age(41,43,46). Hormonal receptors and HER2 are 
rarely positive (39). This tumor has a high local 
reccurence and metastatic potential, and there-
fore, a poor prognosis. Mastectomy with axillary 
dissection is a preff ered surgical choice in the lit-
erature (1,39,43). Adjuvant treatment is based on 
clinical guidelines for invasive adenocarcinoma of 
the breast(39).
2.12  Pleomorphic variant of lobular carcinoma 
(PLC)
Pleomorphic variant of lobular carcinoma is a 
rare variant of invasive lobular carcinoma which 
constitutes less than 1% of all breast cancers (47). 
The mean age of detection is 58.9 years with fre-
quent multifocal and bilateral localization (47,48). 
The tumor is characterized by higher levels of 
Ki67, low ER and PR expression and high HER2 
amplifi cation. This tumor is aggressive and has a 
poor prognosis. The treatment is similar to other 
invasive lobular carcinomas.
2.13 Papillary breast carcinoma
Papillary breast carcinoma accounts for 0.5% 
of all invasive breast cancers. The tumor is com-
posed of epihelialcells arranged around fi brovas-
cular cores, forming a circumscribed mass (49). 
Papillary breast carcinoma can be a divided into 
several histologically subtypes: in situ ductal car-
cinoma which grows inside intraductal papiloma, 
in situ papillary ductal carcinoma, incapsulated 
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papillary carcinoma, solid and invasive papillary 
carcinoma. Unlike benign intraductal papilloma, 
papillary carcinoma does not have a layer of myo-
epithelial cells within the papilla. These tumors 
clinically manifest with a bloody discharge, pal-
pable lump or suspicious mammographic fi nd-
ings (50). Hormonal receptors are mostly positive 
and HER2 is negative. The tumor has a good prog-
nosis. There is no specifi c treatment for papillary 
carcinoma for now.
3.  RARE NON-EPITHELIAN BREAST 
MALIGNANCIES
3.1 Sarcomas
Sarcomas account for less than 1% of all 
breast tumors. Various histological types have 
been described. They most commonly appear in 
the 5th and 6th decade as palpable, painless lumps 
(51). Tumor size varies greatly. The prognosis de-
pends on tumor size and histological type. The 
tumor can spread directly or through the blood 
(52,53). Lymphatic dissemination is very rare 
(54,55). Treatment is multidisciplinary and in-
cludes surgery, chemotherapy and radiation. 
3.1.1 Primary breast lymphoma (PBL)
Primary breast lymphoma (PBL) denotes ma-
lignant lymphomas which primarily appeared in 
the breast in the absence of earlier discovered lym-
phoma in other location. PBL represents less than 
0.5% of all malignant lymphomas (56). B-cell type 
is more common than T-cell type. A painless, fast-
growing mass is dominant in the clinical sett ing 
(56). Diff erentiation of primary and secondary 
lymphoma is diffi  cult, and the following criteria 
are used:
1.  availability of adequate tumor sample
2.  presence of both breast tissue and lympho-
matous infi ltrate in the sample
3.  no distanced disease and previous extra-
mammary lymphoma
4.  ipsilateral axillary lymph node involve-
ment is acceptable (57)
Treatment includes surgery, chemotherapy 
and radiation. Chemotherapeutic treatment of 
stage 2 is defi ned and can be found in the literature. 
Irradiation is used for local control (56). Five-year 
survival is 53%. Local relapse occurs in 12% of pa-
tients, and systemic relapse occurs in 55% of pa-
tients. Favorable prognostic factors are:early stage, 
applicable breast conserving surgery, applied ra-
diation and applied combined treatment (58).
3.1.2 Phyllodes tumor
Phyllodes tumor accounts for less than 1% of 
all breast tumors. The tumor is biphasic, consist-
ing of a stromal and epithelial components. Phyl-
lodes tumor occurs in benign, borderline and ma-
lignant subtypes. It most commonly appears as a 
fast-growing lump in women in their 40s and 50s. 
Phyllodes tumors are similar to fi broadenomas on 
ultrasound, mammography and even on core bi-
opsy specimens. Recurrences usually occur lo-
cally. Recurrence risk factors are tumor positive 
edges, proliferation of connective tissue into the 
surrounding breast tissue and tumor necrosis. He-
matogenous metastases are very rare and occur 
most commonly in the lungs. Mortality due to 
phyllodes tumor is very low (2%). The treatment 
of choice is surgery with a margin greater than 1 
cm. Mastectomy is needed only if it is not possible 
to achieve negative margins with breast conserv-
ing surgery. Since phyllodes tumor rarely metas-
tasizes to the axillary lymph nodes, removal of 
axillary lymph node is not necessary unless they 
are clinically positive. The role of adjuvant irrra-
diation is not completely clear and further re-
search is needed. Although epithelial components 
are often positive for hormone receptors, effi  cacy 
of endocrine treatment has not been proven so far. 
There is also no evidence of the eff ectiveness of 
chemotherapy. Local recurrences are treated by a 
wide excision with negative surgical margins, and 
some members of the NCCN committ ee recom-
mend local radiation after the resection of recur-
rence (59,60).
4. CONCLUSION
Despite breast conserving treatment, surviv-
al in histologically favorable subtypes is very high, 
even comparable to survival of women without 
breast cancer. Patients with tubular, mucinous 
and medullary carcinoma, and malignant phyl-
lodes tumor have such low death rates that an 
even more conservative approach is recommend-
ed in some cases. Since some of these tumors are 
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very rare, specifi c treatment recommendations 
still cannot be defi ned. For that reason treatment 
of rare carcinoma is still based on treatment guide-
lines for common breast cancers. However, when 
deciding on the choice of treatment, known clini-
cal characteristics of rare tumors need to be taken 
into consideration, and individualized multidisci-
plinary approach should be adopted.
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